28.01.2025 • News

Alastair Sanderson Appointed COO at Chemical Business Association

The Chemical Business Association (CBA) has appointed Alastair Sanderson as Chief Operating Officer (COO).

Sanderson brings over 30 years of experience from Unilever, where he focused on Home Care products and played a key role in developing the "Carbon Rainbow" initiative to move towards Net Zero.He holds a First-Class Honours degree in Chemistry and a PhD in Physical Chemistry from The University of Salford. He has held senior R&D roles at Unilever, including Senior Development Manager and Global Technology Manager. He is also a Fellow of the Royal Society of Chemistry (FRSC) and a Chartered Chemist (CChem).

“I would like to welcome Alastair to our CBA Team on behalf of myself, our staff and members," commented CBA CEO Tim Doggett. "Alastair will not only be working closely with me to ensure we continue to deliver the highest levels of service and support, giving the best possible membership experience to our current members, but to ensure our membership continues to grow by providing new innovative services, in addition to bolstering our industry knowledge and know-how.”

Bringing his wide-ranging experience, skillset and strong environmental advocacy to the CBA, Sanderson will be focusing on supporting the CBA’s CEO with day-to-day operations, which will include strategic planning and performance management, amongst other key tasks.

From left to right: Alastair Sanderson (COO, Chemical Business Association) and...
From left to right: Alastair Sanderson (COO, Chemical Business Association) and Tim Dogget (CEO, Chemical Business Association). © Chemical Business Association

Company

Logo:

Chemical Business Association

Group House, Southmere Court
CW1 6GU Crewe
UK

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read